FDA Proposes Curbs on Mass Copycats of Novo, Lilly’s Weight-Loss Drugs

Mariam Sunny, Reuters on April 30, 2026

The FDA’s proposal to remove semaglutide and tirzepatide from a key compounding list could raise prices for millions of Americans using cheaper GLP-1 alternatives.